Achilles Therapeutics (ACHL) Stock Forecast, Price Target & Predictions
ACHL Stock Forecast
Achilles Therapeutics stock forecast is as follows: an average price target of $2.00 (represents a 177.82% upside from ACHL’s last price of $0.72) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ACHL Price Target
The average price target for Achilles Therapeutics (ACHL) is $2.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 177.82% upside from ACHL's last price of $0.72.
ACHL Analyst Ratings
According to 2 Wall Street analysts, Achilles Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ACHL stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Achilles Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 04, 2024 | Joseph Catanzaro | Piper Sandler | $2.00 | $0.90 | 121.51% | 177.82% |
The latest Achilles Therapeutics stock forecast, released on Apr 04, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $2.00, which represents a 121.51% increase from the stock price at the time of the forecast ($0.90), and a 177.82% increase from ACHL last price ($0.72).
Achilles Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.00 |
| Last Closing Price | $0.72 | $0.72 | $0.72 |
| Upside/Downside | -100.00% | -100.00% | 177.82% |
In the current month, the average price target of Achilles Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Achilles Therapeutics's last price of $0.72. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 04, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| Dec 07, 2022 | Chardan Capital | Buy | Buy | Hold |
| Dec 07, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 06, 2022 | Oppenheimer | - | Perform | Downgrade |
Achilles Therapeutics's last stock rating was published by Piper Sandler on Apr 04, 2024. The company Downgrade its ACHL rating from "Overweight" to "Neutral".
Achilles Therapeutics Financial Forecast
Achilles Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Achilles Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ACHL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Achilles Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ACHL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Achilles Therapeutics's previous annual EBITDA (undefined) of $NaN.
Achilles Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-18.97M | $-18.97M | $-18.97M | $-18.97M | $-16.14M | $-16.34M | $-16.55M |
| High Forecast | $-18.97M | $-18.97M | $-18.97M | $-18.97M | $-16.14M | $-15.95M | $-16.55M |
| Low Forecast | $-18.97M | $-18.97M | $-18.97M | $-18.97M | $-16.14M | $-16.34M | $-16.55M |
| Surprise % | - | - | - | - | - | - | - |
Achilles Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ACHL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Achilles Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Achilles Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ACHL last annual SG&A of $NaN (undefined).
Achilles Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.47 | $-0.47 | $-0.47 | $-0.47 | $-0.40 | $-0.41 | $-0.41 |
| High Forecast | $-0.47 | $-0.47 | $-0.47 | $-0.47 | $-0.40 | $-0.40 | $-0.41 |
| Low Forecast | $-0.47 | $-0.47 | $-0.47 | $-0.47 | $-0.40 | $-0.41 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Achilles Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ACHL previous annual EPS of $NaN (undefined).
Achilles Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.32 | $10.00 | 657.58% | Buy |
| CTMX | CytomX Therapeutics | $1.20 | $5.77 | 380.83% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| NUVB | Nuvation Bio | $2.79 | $7.00 | 150.90% | Buy |
| NXTC | NextCure | $1.42 | $3.00 | 111.27% | Buy |
| TIL | Instil Bio | $14.25 | $6.50 | -54.39% | Hold |
ACHL Forecast FAQ
Is Achilles Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Achilles Therapeutics (ACHL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of ACHL's total ratings.
What is ACHL's price target?
Achilles Therapeutics (ACHL) average price target is $2 with a range of $2 to $2, implying a 177.82% from its last price of $0.72. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Achilles Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ACHL stock, the company can go up by 177.82% (from the last price of $0.72 to the average price target of $2), up by 177.82% based on the highest stock price target, and up by 177.82% based on the lowest stock price target.
Can Achilles Therapeutics stock reach $1?
ACHL's average twelve months analyst stock price target of $2 supports the claim that Achilles Therapeutics can reach $1 in the near future.
What are Achilles Therapeutics's analysts' financial forecasts?
Achilles Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-49.033M (high $-48.634M, low $-49.033M), average SG&A $0 (high $0, low $0), and average EPS is $-1.215 (high $-1.205, low $-1.215). ACHL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-75.869M (high $-75.869M, low $-75.869M), average SG&A $0 (high $0, low $0), and average EPS is $-1.88 (high $-1.88, low $-1.88).